摩尔线程公司成立以来的发展情况如何？ 摩尔线程公司成立于 2020 年，专注于 GPU 相关产品的研发与生产。公司致力 于为 AI、数字孪生和科学计算提供计算和加速平台。摩尔线程已经推出了四代 GPU 架构，形成了覆盖智算、高性能计算、图形渲染、虚拟化媒体和个人娱乐 及生产力工具的多元化产品矩阵。公司的主要产品布局包括服务器级、桌面级 和 SoC 级三大场景。 摩尔线程 20250706 摘要 摩尔线程产品线覆盖 AI 智算、图形加速和智能 SoC 三大领域，包括 AI 训练/推理卡、S3,000 系列显卡及 A140/E300 模组，分别应用于 AI 计 算中心、工业设计和 AI PC 边缘等场景。 公司自主研发 Musa 架构，对标英伟达 CUDA 及 AMD CDNA，构建软 硬件全功能 GPU 加速统一架构，兼容国际主流 GPU 生态，提供 AI 计算、 图形渲染及科学计算所需软件技术。 最新一代平湖系列芯片 FP32 算力达 32TFlops，接近英伟达 H100 一 半水平，并已攻克千卡至万卡 GPU 高效互联难题，具备大规模集群通信 高效算力调度能力。 公司 2024 年收入 4.38 亿元，同 ...

Core Viewpoint - The company, Kelun-Botai, is a leading player in the ADC (Antibody-Drug Conjugate) sector, with a robust technology platform and significant backing from multinational corporations (MNCs) [1] Group 1: Company Overview - Kelun-Botai was established in 2016 as an innovative R&D subsidiary of Kelun Pharmaceutical, focusing on three major technology platforms: ADC, macromolecules, and small molecules [1] - As of the 2024 annual report, Kelun-Botai has over 30 innovative assets and more than 10 drugs in clinical stages, indicating a well-structured pipeline [1] - The company is expected to enter a rapid growth phase in 2025, with promising commercial progress anticipated [1] Group 2: ADC Platform Development - The ADC platform focuses on both oncology and non-oncology development strategies, with research capabilities endorsed by MNCs [1] - SKB264, an optimized drug based on trastuzumab, has a comprehensive layout for breast cancer and non-small cell lung cancer (NSCLC), with multiple approvals and submissions expected between 2024 and 2025 [2] - A166 has reached critical endpoints in phase II trials for advanced HER2+ breast cancer and is expected to receive approval in 2025 [2] - The early ADC pipeline includes various targets such as CLDN18.2 and Nectin-4, with new products like SKB571 and SKB107 anticipated to follow [2] Group 3: Non-ADC Platform Development - The non-ADC platform is entering a harvest phase, covering oncology and autoimmune fields [2] - A167 (PD-L1) has received approvals for multiple indications, while A140 (a biosimilar of cetuximab) is also set for approval in early 2025 [2] - A400, a selective RET inhibitor for RET+ NSCLC, is expected to submit for market approval within the year [2] Group 4: Financial Projections - Revenue forecasts for the company from 2025 to 2027 are projected at 2.006 billion, 2.884 billion, and 4.696 billion yuan, reflecting year-on-year growth rates of 3.8%, 43.8%, and 62.8% respectively [3] - The current stock price corresponds to price-to-sales (PS) ratios of 34.7x, 24.2x, and 14.8x for the respective years [3] - The company is expected to reach a commercialization inflection point in 2025, with numerous catalysts from clinical data and business development expectations [3]

摩尔线程主要从事GPU及相关产品的研发、设计和销售。自2020年成立以来，公司以自主研发的全功能 GPU为核心，致力于为AI、数字孪生、科学计算等高性能计算领域提供计算加速平台。 公司已成功推出四代GPU架构，并形成了覆盖AI智算、高性能计算、图形渲染、计算虚拟化、智能媒 体和面向个人娱乐与生产力工具等应用领域的多元计算加速产品矩阵，产品线涵盖政务与企业级智能计 算、数据中心及消费级终端市场，能够满足政府、企业和个人消费者等在不同市场中的差异化需求。新 一代架 构相关产品处于研发阶段，同步推进高性能GPU芯片和智算集群前沿技术预研，以自主创新为 核心，持续推动计算产业向通用化与智能化方向发展。 6月30日，上交所正式受理摩尔线程智能科技（北京）股份有限公司（简称：摩尔线程）科创板IPO申 请。 桌面级图形加速产品主要应用于AI PC、游戏PC及办公PC等场景的GPU及相关产品，包括MTT S80/S70/S50/S30/S10/X300/X100 等系列显卡，以及基于前述显卡打造的工作站等。该类产品支持 Windows、麒麟KylinOS、统信UOS、openEuler 等多款国内外主流操作系统，以及Inte ...